

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Canagliflozin in combination therapy for treating
type 2 diabetes**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

One consultee suggested that since the NICE Clinical Guideline states that for people of non-European descent the body mass index threshold for treatment with GLP-1 agonists is adjusted downward as that are at high risk of developing type 2 diabetes. A similar adjustment is recommended for these ethnic groups in the NICE guidance for liraglutide and exenatide prolonged release.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

This issue was discussed at the workshop. Workshop attendees did not consider that the population for this appraisal depended on body mass index values. It was therefore considered that this is not an equality issue and does not need to be reflected in the scope.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the draft remit or draft scope are required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No additional stakeholders were identified.

Approved by Associate Director (name):

Date: [xx/xx/year]